|
Lupus Erythematosus, Systemic
|
0.300 |
AlteredExpression
|
disease |
BEFREE |
We demonstrated that female lupus CD4+ T cells and demethylated CD4+ T cells express high level of CD40LG and overstimulate B cells to produce IgG.
|
19520616 |
2009 |
|
Lupus Erythematosus, Systemic
|
0.300 |
AlteredExpression
|
disease |
BEFREE |
Taken together, our data provide evidence that E4BP4 can inhibit CD40L expression through epigenetic modifications in the promoter region of CD40L, thus negatively regulating self-reactivity of SLE CD4(+) T cells.
|
23340290 |
2013 |
|
Lupus Erythematosus, Systemic
|
0.300 |
Biomarker
|
disease |
MGD |
|
|
|
|
Lupus Erythematosus, Systemic
|
0.300 |
AlteredExpression
|
disease |
BEFREE |
Thus, these findings provide some of the first evidence to support a possible mechanistic link to explain how the overexpression of IL-15 observed in lupus patients may be involved in the prolonged expression of CD154 that has also been observed on lupus CD4 T cells.
|
24500400 |
2014 |
|
Lupus Erythematosus, Systemic
|
0.300 |
Biomarker
|
disease |
LHGDN |
Platelets from patients with SLE can activate mesangial cells through CD40/CD154 interactions, leading to an induction of proliferation of the mesangial cells and an enhanced production of TGF-beta1, a profibrotic cytokine.
|
16221206 |
2005 |
|
Lupus Erythematosus, Systemic
|
0.300 |
Biomarker
|
disease |
BEFREE |
Epigenetic deregulation of genes encoded on the X chromosome as reported for CD40L in lupus could explain the female predominance of autoimmune diseases.
|
24117612 |
2014 |
|
Lupus Erythematosus, Systemic
|
0.300 |
AlteredExpression
|
disease |
LHGDN |
Engagement of beta1 integrin on T cells from patients with active SLE, but not on those from normal individuals, induced cell proliferation as well as CD40L expression on T cells.
|
17469136 |
2007 |
|
Lupus Erythematosus, Systemic
|
0.300 |
GeneticVariation
|
disease |
BEFREE |
The CD154 3'UTR microsatellite is associated with SLE, and the most represented alleles in patients were accompanied by a more prolonged protein expression in activated lymphocytes from controls.
|
14962968 |
2004 |
|
Lupus Erythematosus, Systemic
|
0.300 |
Biomarker
|
disease |
BEFREE |
The CD40-CD40L pathway is a promising treatment target for autoimmune diseases such as rheumatoid arthritis, systemic lupus erythematosus and lupus nephritis.
|
29127458 |
2018 |
|
Lupus Erythematosus, Systemic
|
0.300 |
AlteredExpression
|
disease |
BEFREE |
We determined PECAM-1 polymorphisms, soluble PECAM-1, and CD40L levels in rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE) and evaluated their associations with clinical atherosclerotic complications.
|
25201689 |
2014 |
|
Lupus Erythematosus, Systemic
|
0.300 |
Biomarker
|
disease |
BEFREE |
These data suggest that the presence of two X chromosomes may predispose to SLE, the ligand (CD40 ligand) for one of the genes that contributes to the pathogenesis of SLE being located on the X chromosome.
|
26936892 |
2016 |
|
Lupus Erythematosus, Systemic
|
0.300 |
Biomarker
|
disease |
BEFREE |
The effect of anti-CD40 ligand antibody on B cells in human systemic lupus erythematosus.
|
12115186 |
2002 |
|
Lupus Erythematosus, Systemic
|
0.300 |
AlteredExpression
|
disease |
BEFREE |
Strikingly, an autoreactivity profile defined by IgG anti-Ro/La was associated with reduced levels of specific natural IgM targeting phosphorylcholine (PC) antigens and malondialdehyde (MDA) modified-protein, as well as total IgM, while no differences were detected in SLE patients with an autoreactivity profile defined by anti-cardiolipin/β<sub>2</sub>glycoprotein-I.
|
28919518 |
2017 |
|
Lupus Erythematosus, Systemic
|
0.300 |
AlteredExpression
|
disease |
BEFREE |
These results suggest that engagement of beta1 integrins on SLE T cells could induce FAK-mediated signaling and subsequent CD40L expression and proliferation.
|
17469136 |
2007 |
|
Lupus Erythematosus, Systemic
|
0.300 |
Biomarker
|
disease |
BEFREE |
We have previously demonstrated that DNA demethylation of CD40L on the X chromosome is responsible for female susceptibility to systemic lupus erythematosus (SLE).
|
22889643 |
2012 |
|
Lupus Erythematosus, Systemic
|
0.300 |
AlteredExpression
|
disease |
BEFREE |
Furthermore, CD40L expression on T cells upon activation was enhanced in SLE patients.
|
12673892 |
2003 |
|
Lupus Erythematosus, Systemic
|
0.300 |
Biomarker
|
disease |
BEFREE |
These novel findings underscore the multiplicity of pathways through which monocytes may contribute to SLE pathology and suggest that T cell-independent CD40L-mediated cell to cell interactions may be also involved in humoral immune activation in SLE.
|
11987985 |
2002 |
|
Lupus Erythematosus, Systemic
|
0.300 |
Biomarker
|
disease |
BEFREE |
Because hydroxychloroquine (HCQ) has been used frequently in the treatment of lupus, we sought to identify the effects of HCQ on CD154 and a possibly regulatory mechanism.
|
28793932 |
2017 |
|
Lupus Erythematosus, Systemic
|
0.300 |
AlteredExpression
|
disease |
LHGDN |
The levels of sCD30 and of sCD40L in a group of patients with systemic lupus erythematodes and their diagnostic value.
|
17103120 |
2007 |
|
Lupus Erythematosus, Systemic
|
0.300 |
Biomarker
|
disease |
BEFREE |
This activity was inhibited by anti-CD40L antibody, as well as anti-CD1d antibody, confirming a role for CD40L-CD40 and TCR-CD1d interactions in lupus iNKT-cell-mediated help.
|
25352488 |
2015 |
|
Lupus Erythematosus, Systemic
|
0.300 |
AlteredExpression
|
disease |
BEFREE |
3H - TdR incorporation of SLE B cells without stimuli (P<0.001) and with CD40L-LZ stimulation (P<0.05) were significantly lower in SLE patients compared with normal controls.
|
10342716 |
1999 |
|
Lupus Erythematosus, Systemic
|
0.300 |
AlteredExpression
|
disease |
LHGDN |
Neither cell-surface nor soluble CD154 levels are associated with coronary artery disease in systemic lupus erythematosus.
|
18260168 |
2008 |
|
Lupus Erythematosus, Systemic
|
0.300 |
AlteredExpression
|
disease |
BEFREE |
Association study of CD154 polymorphisms and serum CD154 level with systemic lupus erythematous in Chinese population.
|
28550400 |
2017 |
|
Lupus Erythematosus, Systemic
|
0.300 |
Biomarker
|
disease |
BEFREE |
Culture of SLE T cells in medium containing 2-fluoroestradiol followed by T cell receptor (TCR) activation for 2 h using anti-CD3 resulted in a significant (p = 0.04) estrogen dependent increase in CD40L mRNA.
|
11764210 |
2001 |
|
Lupus Erythematosus, Systemic
|
0.300 |
Biomarker
|
disease |
BEFREE |
Anti-CD40 ligand antibody treatment prevents the development of lupus-like nephritis in a subset of New Zealand black x New Zealand white mice. Response correlates with the absence of an anti-antibody response.
|
8816428 |
1996 |